Welcome to our dedicated page for Emmaus Life Scie news (Ticker: EMMA), a resource for investors and traders seeking the latest updates and insights on Emmaus Life Scie stock.
Emmaus Life Sciences, Inc. (OTCQB: EMMA) is a commercial-stage biopharmaceutical company that describes itself as a leader in the treatment of sickle cell disease. Its news flow centers on Endari®, a prescription-grade L-glutamine oral powder indicated to reduce the acute complications of sickle cell disease in adults and children five years of age and older. Emmaus’ press releases provide regular updates on Endari’s regulatory status, geographic reach, and commercial performance.
On this page, readers can follow EMMA news related to quarterly and annual financial results, where the company reports net revenues from Endari sales, operating expenses, income or loss from operations, and liquidity. These updates often discuss factors such as inventory availability, competition from generic L-glutamine oral powder, and changes in operating cost structures, giving context to the company’s financial trajectory.
Emmaus also issues news about regulatory milestones, such as FDA approval of label enhancements for Endari based on post-marketing pharmacokinetic data. The company has highlighted label changes that clarify dosing by body weight, confirm no unwanted accumulation with twice-daily dosing, and allow administration with or without food. In addition, announcements have covered developments in international markets, including market exclusivity for Endari in the Kingdom of Saudi Arabia and the product’s availability on a named patient or early access basis in several countries.
Corporate and capital structure events appear in Emmaus news as well, including Exchange Agreements for outstanding notes and changes in leadership roles. Investors and observers can use this EMMA news feed to review how Emmaus communicates its strategy around Endari, responds to competitive dynamics, and manages licensing and distribution arrangements. For ongoing insight into the company’s sickle cell disease franchise and related corporate actions, this page aggregates Emmaus Life Sciences’ latest press releases and disclosures.
Emmaus Life Sciences, Inc. (OTCQX: EMMA), based in Torrance, California, will participate in two investor conferences in May 2022. The first event, the Q2 Investor Summit, will occur on May 3-4, where CEO Yutaka Niihara will present at 3:30 p.m. ET. The H.C Wainwright Global Investment Conference is scheduled for May 23-26, with an on-demand presentation available from May 24, 2022, at 7:00 a.m. ET. One-on-one meetings can be arranged with management during both conferences.
Emmaus Life Sciences (OTQXC: EMMA) has launched a full-service telehealth solution to enhance access to its product Endari®, an L-glutamine oral powder for sickle cell disease treatment. This initiative, in partnership with Asembia LLC, US Bioservices Corporation, and UpScript IP Holdings, enables patients to receive prescriptions and home delivery, improving patient experience and adherence rates. With the telehealth market experiencing significant growth, Emmaus aims to reach new patients and generate revenue through this innovative service.
Emmaus Life Sciences (OTCQX: EMMA) reported significant findings from a study on Endari®, an oral L-glutamine powder, in treating sickle cell disease. Conducted in French Guiana and Qatar, the observational study showed that patients had fewer vaso-occlusive crises and hospitalizations over 72 weeks compared to baseline, with statistically significant reductions in blood transfusions and improved hemoglobin levels. The study, presented at the 62nd Annual Meeting of the British Society for Haematology, reinforces the effectiveness of Endari in enhancing patient outcomes for sickle cell disease.
Emmaus Life Sciences announced that Florida has approved the inclusion of Endari, its prescription-grade L-glutamine oral powder, on the Medicaid Preferred Drug List (PDL) starting April 1, 2022. This decision means Endari can be prescribed without prior authorization, streamlining access for patients suffering from sickle cell disease. Florida joins several other states in eliminating prior authorization for this medication. CEO Yutaka Niihara emphasized that this approval brings them closer to making Endari widely available to healthcare providers.
On March 23, 2022, Emmaus Life Sciences announced the U.A.E. Ministry of Health approved its marketing application for Endari®, a treatment for sickle cell disease. After a five-month review, Endari was previously available only on an early access basis. Emmaus estimates about 600 sickle cell patients reside in the U.A.E. and approximately 225,000 in the MENA region could benefit from the drug. The company aims to secure further approvals across Gulf Cooperation Council states, highlighting the significance of this market due to the higher prevalence of sickle cell disease compared to the U.S.
Emmaus Life Sciences (OTCQX: EMMA) announced that Yutaka Niihara, CEO, will present a company overview at the H.C. Wainwright BioConnect Conference from January 10-13, 2021. The presentation will be available on-demand starting at 7:00 a.m. Eastern Time on January 10, and can be accessed on Emmaus' website. Emmaus Life Sciences is a leader in treating sickle cell disease and markets the FDA-approved Endari® (L-glutamine powder) for reducing complications related to this condition.
Emmaus Life Sciences (OTCQX: EMMA) announced positive transfusion data from a post-hoc analysis of its phase 3 clinical study of Endari, an L-glutamine oral powder for sickle cell disease (SCD). Presented at the 63rd ASH Annual Meeting, the study showed that patients on Endari required approximately 43% fewer units of red blood cells compared to those on placebo over 48 weeks. The multicenter trial included 230 patients, indicating that Endari significantly reduces pain crises and hospitalizations. This highlights its potential as a complementary therapy alongside hydroxyurea.
Emmaus Life Sciences (OTCQX: EMMA) announced that its CEO, Yutaka Niihara, will present live on VirtualInvestorConferences.com on December 16 at 12:30 PM ET. Investors can engage with the company during this interactive online event, which will also be archived for later viewing. Attendees are encouraged to pre-register and check their systems for a smooth experience. Emmaus Life Sciences specializes in treating sickle cell disease and markets FDA-approved Endari, aimed at reducing acute complications of the condition.
Emmaus Life Sciences, Inc. (OTCQX: EMMA) announced that data on Endari®, its L-glutamine oral powder for sickle cell disease, will be presented at the 63rd American Society of Hematology Annual Meeting from December 11-14, 2021. The study, titled 'The Evaluation of Transfusion Data from the Phase 3 Clinical Study of L-Glutamine in Sickle Cell Disease,' will be presented on December 13, 2021. Endari® has been approved since July 2017 and is marketed to reduce complications of sickle cell disease in patients aged 5 and older. For further information, visit Emmaus' website.
Emmaus Life Sciences (OTCQX: EMMA) reported Q3 2021 net revenues of $5.8 million, up 3% year-over-year but down 6% from Q2 2021. For the nine months ending September 30, 2021, revenues increased 4% to $17.6 million. Operating loss for Q3 2021 was $31,000, compared to $8,000 in Q3 2020, with a net loss of $3.2 million. The company expanded access to its sickle cell treatment, Endari, through a partnership with UpScript and entered an agreement with Asembia for provider support. Emmaus also submitted a marketing application for Endari in the UAE and secured a license for Kainos' IRAK4 inhibitor.